Get the Stockscreener App
23.21
5.36%
1.18
After Hours:
23.73
0.52
+2.24%
Arcturus Therapeutics Holdings Inc stock is traded at $23.21, with a volume of 421.22K.
It is up +5.36% in the last 24 hours and up +10.00% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
See More
Previous Close:
$22.03
Open:
$21.69
24h Volume:
421.22K
Relative Volume:
0.98
Market Cap:
$631.71M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
7.7625
EPS:
2.99
Net Cash Flow:
$-21.00M
1W Performance:
+9.74%
1M Performance:
+10.00%
6M Performance:
-31.27%
1Y Performance:
-9.16%
1-Day Range:
$21.55
$23.55
1-Week Range:
$20.89
$23.55
52-Week Range:
$17.52
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Yahoo Finance
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - Longview News-Journal
Here's Why Investors Should Invest in Arcturus Stock Now - MSN
American Century Companies Inc. Sells 129,706 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Deerfield Management Company L.P. Series C Takes $958,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences - Yahoo Finance
XTX Topco Ltd Invests $596,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Trading 4.3% Higher - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.5% - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - Defense World
Cystic Fibrosis (CF) Therapeutics Market Report 2024: Global Size, Share, Growth, Trends, Forecast To 2033 - WhaTech
Quest Partners LLC Raises Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 6.6% - MarketBeat
Arcturus Therapeutics Holdings Inc (ARCT) expanding its growth trajectory ahead - SETE News
Here's Why Investors Should Invest in Arcturus Stock Now - Yahoo Finance
Arcturus Therapeutics Holdings Inc [ARCT] Insider Activity: An Update for Investors - Knox Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Bank of New York Mellon Corp Has $2.90 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Principal Financial Group Inc. Has $406,000 Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - PR Newswire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - StockTitan
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - StockTitan
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.5% - MarketBeat
Top High Growth Tech Stocks to Watch in September 2024 - Simply Wall St
Charting the Course: Arcturus Therapeutics Holdings Inc’s ARCT Stock Prospects - The InvestChronicle
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting RevenueTechnavio - The Malaysian Reserve
Analyzing Arcturus Therapeutics Holdings Inc (ARCT) After Recent Trading Activity - Knox Daily
Arcturus Therapeutics’ (ARCT) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According To Short Sellers - Insider Monkey
Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers - Insider Monkey
Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 21,737 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation - Simply Wall St
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average of $28.74 - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average of $28.74 - Defense World
Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect? - Benzinga
FDA greenlights Arcturus cystic fibrosis treatment study - Investing.com
FDA greenlights Arcturus cystic fibrosis treatment study By Investing.com - Investing.com Canada
FDA greenlights Arcturus cystic fibrosis treatment study By Investing.com - Investing.com UK
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis - Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis - StockTitan
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? - Yahoo Finance
Leerink Partners initates Arcturus Therapeutics Holdings Inc (ARCT) stock to an Outperform - Knox Daily
Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 5.6% - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences - StockTitan
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock - Yahoo Finance
New Strong Buy Stocks for August 23rd - MSN
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Buy” from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):